A growing number of individuals are being diagnosed with Attention Deficit Hyperactivity Disorder (ADHD), but a significant concern exists regarding the proper disclosure of potentially life-threatening side effects associated with their medication, according to psychiatrist Dr. Max Pemberton.

Dr. Pemberton recounted a case where a seemingly healthy patient in his forties suffered a cardiac arrest while on vacation. The patient had no prior history of heart issues, and investigations by a cardiologist eventually raised the question of whether his long-term ADHD medication might have played a role. This incident prompted Dr. Pemberton to investigate further, revealing what he describes as a concerning lack of data on the long-term cardiac effects of these drugs.

He noted that the average clinical trial for ADHD medication lasts only about 75 days, serving as the primary evidence base for prescribing these drugs to children and maintaining them for decades. Medical training, he stated, offered little information on the long-term cardiovascular impact until recently.

A 2024 study by Swedish researchers, which followed 278,000 individuals with ADHD for up to 14 years, found a correlation between the duration of medication use and an increased risk of heart disease. The study indicated that after five years of treatment, the risk of heart disease rose by nearly a quarter, and the risk of high blood pressure increased by 80 percent. The study also suggested that higher doses were associated with greater risks.

Despite these findings, Dr. Pemberton observed a prevailing attitude that these medications are harmless. He highlighted that methylphenidate and lisdexamfetamine, two common ADHD medications, are classified as Schedule 2 controlled drugs, placing them in the same legal category as morphine and fentanyl due to their potential for abuse.

This trend has coincided with a significant rise in prescriptions. Prescribing of ADHD medication to women over 25 in Britain, for instance, has increased more than twentyfold since 2010. Dr. Pemberton attributes this partly to